Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Hua Medicine Files for Hong Kong IPO -- Rumors Predict a $200 Million Debut

publication date: Jun 7, 2018

Hua Medicine, a Beijing biopharma, announced its IPO application was accepted by the Hong Kong exchange. According to rumors, the company hopes to raise $200 million in the offering. Hua, a company testing a treatment for type 2 diabetes, is the second pre-revenue China biopharma accepted to IPO in Hong Kong under new exchange rules. In fact, Hua's prospectus revealed it lost $50 million in Q1 of 2018, more than the $44 million it lost in all of 2017. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020